Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators

Target: CX3CR1 Composite Score: 0.503 Price: $0.51 Citation Quality: Pending neurodegeneration Status: debated
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration
🏆 ChallengeSolve: Microglia-astrocyte crosstalk amplification loops in neurodegen$109K bounty →
✓ All Quality Gates Passed
Quality Report Card click to collapse
C+
Composite: 0.503
Top 39% of 561 hypotheses
T1 Established
Multi-source converged and validated
T0 Axiom requires manual override only
B Mech. Plausibility 15% 0.65 Top 60%
B Evidence Strength 15% 0.60 Top 56%
A Novelty 12% 0.80 Top 41%
C+ Feasibility 12% 0.50 Top 64%
B+ Impact 12% 0.70 Top 53%
B+ Druggability 10% 0.75 Top 37%
C+ Safety Profile 8% 0.55 Top 54%
A Competition 6% 0.85 Top 28%
B Data Availability 5% 0.60 Top 59%
C+ Reproducibility 5% 0.55 Top 63%
Evidence
26 supporting | 8 opposing
Citation quality: 100%
Debates
2 sessions B
Avg quality: 0.61
Convergence
0.41 C 30 related hypothesis share this target

From Analysis:

Synaptic pruning by microglia in early AD

Synaptic pruning by microglia in early AD

→ View full analysis & debate transcript

Hypotheses from Same Analysis (6)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.480 | Target: P2RY12
Complement C1q Mimetic Decoy Therapy
Score: 0.479 | Target: C1QA
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.424 | Target: ANXA1
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.411 | Target: TREM2
Metabolic Reprogramming via Microglial Glycolysis Inhibition
Score: 0.385 | Target: HK2
Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins
Score: 0.384 | Target: CX3CR1

→ View full analysis & all 7 hypotheses

Description

Molecular Mechanism and Rationale

The fractalkine/CX3CR1 signaling axis represents a critical communication pathway between neurons and microglia that maintains homeostatic brain function through precise regulation of microglial activity states. Fractalkine (CX3CL1) is a unique chemokine that exists in both membrane-bound and soluble forms, with the membrane-bound form serving as the primary ligand for the CX3CR1 receptor exclusively expressed on microglia in the central nervous system. Under physiological conditions, constitutive neuronal fractalkine expression maintains microglia in a surveillant, ramified state characterized by dynamic process extension and retraction that monitors synaptic activity without engaging in destructive phagocytosis.

...

Figures & Visualizations

Pathway diagram for CX3CR1
Pathway diagram for CX3CR1 pathway diagram
Score comparison (7 hypotheses)
Score comparison (7 hypotheses) score comparison
Evidence heatmap for TREM2 (8 hypotheses)
Evidence heatmap for TREM2 (8 hypotheses) evidence heatmap
Pathway diagram for HK2
Pathway diagram for HK2 pathway diagram
Debate overview for sda-2026-04-01-gap-v2-691b42f1
Debate overview for sda-2026-04-01-gap-v2-691b42f1 debate overview
Evidence heatmap for CX3CR1 (2 hypotheses)
Evidence heatmap for CX3CR1 (2 hypotheses) evidence heatmap

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.65 (15%) Evidence 0.60 (15%) Novelty 0.80 (12%) Feasibility 0.50 (12%) Impact 0.70 (12%) Druggability 0.75 (10%) Safety 0.55 (8%) Competition 0.85 (6%) Data Avail. 0.60 (5%) Reproducible 0.55 (5%) 0.503 composite
34 citations 34 with PMID 24 medium Validation: 100% 26 supporting / 8 opposing
Evidence Matrix — sortable by strength/year, click Abstract to expand
ClaimTypeSourceStrength ↕Year ↕Quality ↕PMIDsAbstract
CX3CR1 deficiency accelerates tau pathology and ne…SupportingNature MEDIUM20100.00PMID:20980594
Fractalkine (CX3CL1) overexpression reduces amyloi…SupportingFASEB J MEDIUM20140.00PMID:25157208
CX3CL1-CX3CR1 signaling maintains microglia in sur…SupportingScience MEDIUM20110.00PMID:21778362
AZD8797 defines a druggable allosteric site on CX3…SupportingJ Med Chem MEDIUM20160.00PMID:27156590
Fractalkine signaling declines with aging contribu…SupportingAging Cell MEDIUM20170.00PMID:28133889
Recombinant CX3CL1 protects dopaminergic neurons f…SupportingPNAS MEDIUM20180.00PMID:30021162
Fractalkine Enhances Hematoma Resolution and Impro…SupportingStroke MEDIUM20230.33PMID:37465997
Neuronal cathepsin S increases neuroinflammation a…SupportingAging Cell MEDIUM20250.00PMID:39453382
Liver Immune Profiling Reveals Pathogenesis and Th…SupportingCell MEDIUM20200.00PMID:33248023
CX3CL1/CX3CR1 signaling targets for the treatment …SupportingPharmacol Ther MEDIUM20220.33PMID:34492237
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-I…SupportingInt J Mol Sci MEDIUM20240.00PMID:38731899
Constitutive expression of CX3CR1-BAC-Cre introduc…SupportingBiochem Biophys… MEDIUM20260.00PMID:41924777
Microglia-glioblastoma crosstalk mediates glioblas…SupportingImmunity MEDIUM20260.00PMID:41923645
Identification of suicide brain transcriptomic sig…SupportingTransl Psychiat… MEDIUM20260.00PMID:41916959
G-protein coupled receptor chemokine CX3CR1 influe…SupportingAdv Protein Che… MEDIUM20260.00PMID:41904008
Conserved ductular reaction mechanisms in biliary …SupportingCell Mol Gastro… MEDIUM20260.00PMID:41903685
Identifies immunological mechanisms of neuroprotec…SupportingFront Aging Neu… MODERATE20260.00PMID:41788408
Directly discusses chemokine networks and blood-br…SupportingBiomolecules STRONG20260.00PMID:41897331
Directly examines CX3CL1/CX3CR1 axis dysregulation…SupportingActa Neuropatho… STRONG2026-PMID:41863015
[Corrigendum] Influence of aspirin on the CX3CL1/C…SupportingInt J Mol Med-20260.00PMID:41930567-
CX3CR1-T280M polymorphism and end-stage renal dise…SupportingSci Rep-20260.00PMID:41932952-
NIK-driven IL-23 production by myeloid cells is a …SupportingJ Exp Med-20260.00PMID:41758203-
Aging effects on emotionality, cognition and brain…SupportingNPJ Aging-20260.00PMID:41946716-
CD8(+) T(EMRA) cells: A double-edged sword in immu…SupportingInt Immunopharm…-20260.00PMID:41946125-
Expression of MS4A4A on synovial infiltrating macr…SupportingImmunol Med-20260.00PMID:41955527-
Role of Cannabinoid Receptor Type 2 in Acute Behav…SupportingCannabis Cannab…-20260.00PMID:41958320-
Error fetchingOpposingJ Inflamm Res MEDIUM20220.33PMID:35642214
Microglia in neurodegeneration.OpposingNat Neurosci MEDIUM20180.33PMID:30258234
Constitutive expression of CX3CR1-BAC-Cre introduc…OpposingbioRxiv MEDIUM20240.00PMID:39554070
How neuroinflammation contributes to neurodegenera…OpposingScience MEDIUM20160.33PMID:27540165
CX3CL1/CX3CR1 signaling targets for the treatment …OpposingPharmacol Ther MEDIUM20220.33PMID:34492237
G-protein coupled receptor chemokine CX3CR1 influe…OpposingAdv Protein Che… MEDIUM20260.00PMID:41904008
Glial Cells in the Early Stages of Neurodegenerati…OpposingInt J Mol Sci MEDIUM20250.00PMID:41465422
CX3CR1: a potential microglia-specific PET imaging…OpposingFront Pharmacol MEDIUM20250.00PMID:41424797
Legacy Card View — expandable citation cards

Supporting Evidence 26

CX3CR1 deficiency accelerates tau pathology and neurodegeneration in tauopathy mouse models MEDIUM
Nature · 2010 · PMID:20980594 · Q:0.00
ABSTRACT

Somatostatin-expressing inhibitory (SOM) neurons in the sensory cortex consist mostly of Martinotti cells, which project ascending axons to layer 1. Due to their sparse distribution, the representational properties of these neurons remain largely unknown. By two-photon imaging guided cell-attached recordings, we characterized visual response and receptive field (RF) properties of SOM neurons and parvalbumin-expressing inhibitory (PV) neurons genetically labeled in the mouse primary visual cortex. In contrast to PV neurons, SOM neurons exhibit broader spikes, lower spontaneous firing rates, smaller On/Off subfields, and broader ranges of basic RF properties such as On/Off segregation, orientation and direction tunings. Notably, the level of orientation and direction selectivity is comparable to that of excitatory neurons, from weakly-tuned to highly selective, whereas PV neurons are in general unselective. Strikingly, the evoked spiking responses of SOM cells are ∼3- to 5-fold weaker an

Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse mode… MEDIUM
Fractalkine (CX3CL1) overexpression reduces amyloid pathology and preserves synapses in Alzheimer's mouse models
FASEB J · 2014 · PMID:25157208 · Q:0.00
ABSTRACT

Argyrophylic grain disease (AGD) is a neurodegenerative condition that has been classified among the sporadic tauopathies. Entities in this group present intracellular aggregates of hyperphosphorylated tau, giving rise to characteristic neuronal and glial inclusions. In different tauopathies, the proportion of several tau isoforms present in the aggregates shows specific patterns. AGD has been tentatively classified in the 4R group (predominance of 4R tau isoforms) together with progressive supranuclear palsy and corticobasal degeneration. Pick's disease is included in the 3R group (predominance of 3R isoforms), whereas tau pathology of Alzheimer's disease represents and intermediate group (3 or 4 repeats [3R plus 4R, respectively] isoforms). In this work, we have analyzed tau present in aggregates isolated from brain samples of patients with argyrophylic grain disease. Our results indicate that the main tau isoform present in aggregates obtained from patients with AGD is a hyperphosph

CX3CL1-CX3CR1 signaling maintains microglia in surveillant state and prevents aberrant synaptic pruning MEDIUM
Science · 2011 · PMID:21778362 · Q:0.00
ABSTRACT

Microglia are highly motile phagocytic cells that infiltrate and take up residence in the developing brain, where they are thought to provide a surveillance and scavenging function. However, although microglia have been shown to engulf and clear damaged cellular debris after brain insult, it remains less clear what role microglia play in the uninjured brain. Here, we show that microglia actively engulf synaptic material and play a major role in synaptic pruning during postnatal development in mice. These findings link microglia surveillance to synaptic maturation and suggest that deficits in microglia function may contribute to synaptic abnormalities seen in some neurodevelopmental disorders.

AZD8797 defines a druggable allosteric site on CX3CR1 — structure enables PAM design MEDIUM
J Med Chem · 2016 · PMID:27156590 · Q:0.00
ABSTRACT

In addition to allowing much greater technical precision, the modern era allows investigation of target physiology and it is the potential incorporation of physiologic information into the treatment-planning rubric that gives modern PET-CT its allure and promise. Although oncologic PET scanning has been clinically available for more than 10 years, it is only recently that sufficient investigative and retrospective data have become available to confidently assert that future radiotherapy treatment planning will include functional imaging as an obligatory dimension of clinical characterization for most gynecologic tumors. This article explores the role of functional imaging in radiotherapy planning and management of gynecologic malignancies.

Fractalkine signaling declines with aging contributing to age-related neuroinflammation and synapse loss MEDIUM
Aging Cell · 2017 · PMID:28133889 · Q:0.00
ABSTRACT

A novel Ni foam-Ni3 S2 @Ni(OH)2 -graphene sandwich-structured electrode (NF-NN-G) with high areal mass loading (8.33 mg cm-2 ) has been developed by sulfidation and hydrolysis reactions. The conductivity of Ni3 S2 and Ni(OH)2 were both improved. The upper layer of Ni(OH)2 , covered with a thin graphene film, is formed in situ from the surface of the lower layer of Ni3 S2 , whereas the Ni3 S2 grown on Ni foam substrate mainly acts as a rough support bridging the Ni(OH)2 and Ni foam. The graphene stabilized the Ni(OH)2 and the electrochemical properties were effectively enhanced. The as-synthesized NF-NN-G-5mg electrode shows a high specific capacitance (2258 F g-1 at 1 A g-1 or 18.81 F cm-2 at 8.33 mA cm-2 ) and an outstanding rate property (1010 F g-1 at 20 Ag-1 or 8.413 F cm-2 at 166.6 mA cm-2 ). This result is around double the capacitance achieved in previous research on Ni3 S2 @Ni(OH)2 /3DGN composites (3DGN=three-dimensional graphene network). In addition, the as-fabricated NF-NN-

Recombinant CX3CL1 protects dopaminergic neurons from α-synuclein-induced microglial phagocytosis MEDIUM
PNAS · 2018 · PMID:30021162 · Q:0.00
ABSTRACT

Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T cells is the foundation of adoptive T cell therapy (ACT) and has been shown to elicit significant tumor regression. However, therapy-induced selective pressure can sculpt the antigenicity of tumors, resulting in outgrowth of variants that lose the target antigen. We demonstrate that tumor relapse from ACT and subsequent oncolytic viral vaccination can be prevented using class I HDACi, MS-275. Drug delivery subverted the phenotype of tumor-infiltrating CD11b+ Ly6Chi Ly6G- myeloid cells, favoring NOS2/ROS secretion and pro-inflammatory genes characteristic of M1 polarization. Simultaneously, MS-275 abrogated the immunosuppressive function of tumor-infiltrating myeloid cells and reprogrammed them to eliminate antigen-negative tumor cells in a caspase-dependent manner. Elevated IFN-γ within the tumor microenvironment suggests that MS-275 modulates the local cytokine landscape to favor antitumor myeloid polarization through

Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway Afte… MEDIUM
Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway After GMH.
Stroke · 2023 · PMID:37465997 · Q:0.33
ABSTRACT

BACKGROUND: Hematoma clearance has been a proposed therapeutic strategy for hemorrhagic stroke. This study investigated the impact of CX3CR1 (CX3C chemokine receptor 1) activation mediated by r-FKN (recombinant fractalkine) on hematoma resolution, neuroinflammation, and the underlying mechanisms involving AMPK (AMP-activated protein kinase)/PPARγ (peroxisome proliferator-activated receptor gamma) pathway after experimental germinal matrix hemorrhage (GMH). METHODS: A total of 313 postnatal day 7 Sprague Dawley rat pups were used. GMH was induced using bacterial collagenase by a stereotactically guided infusion. r-FKN was administered intranasally at 1, 25, and 49 hours after GMH for short-term neurological evaluation. Long-term neurobehavioral tests (water maze, rotarod, and foot-fault test) were performed 24 to 28 days after GMH with the treatment of r-FKN once daily for 7 days. To elucidate the underlying mechanism, CX3CR1 CRISPR, or selective CX3CR1 inhibitor AZD8797, was administer

Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-… MEDIUM
Neuronal cathepsin S increases neuroinflammation and causes cognitive decline via CX3CL1-CX3CR1 axis and JAK2-STAT3 pathway in aging and Alzheimer's disease.
Aging Cell · 2025 · PMID:39453382 · Q:0.00
ABSTRACT

Aging is an intricate process involving interactions among multiple factors, which is one of the main risks for chronic diseases, including Alzheimer's disease (AD). As a member of cysteine protease, cathepsin S (CTSS) has been implicated in inflammation across various diseases. Here, we investigated the role of neuronal CTSS in aging and AD started by examining CTSS expression in hippocampus neurons of aging mice and identified a significant increase, which was negatively correlated with recognition abilities. Concurrently, we observed an elevation of CTSS concentration in the serum of elderly people. Transcriptome and fluorescence-activated cell sorting (FACS) results revealed that CTSS overexpression in neurons aggravated brain inflammatory milieu with microglia activation to M1 pro-inflammatory phenotype, activation of chemokine C-X3-C-motif ligand 1 (CX3CL1)-chemokine C-X3-C-motif receptor 1 (CX3CR1) axis and janus kinase 2 (JAK2)-signal transducer and activator of transcription 3

Liver Immune Profiling Reveals Pathogenesis and Therapeutics for Biliary Atresia. MEDIUM
Cell · 2020 · PMID:33248023 · Q:0.00
ABSTRACT

Biliary atresia (BA) is a severe cholangiopathy that leads to liver failure in infants, but its pathogenesis remains to be fully characterized. By single-cell RNA profiling, we observed macrophage hypo-inflammation, Kupffer cell scavenger function defects, cytotoxic T cell expansion, and deficiency of CX3CR1+effector T and natural killer (NK) cells in infants with BA. More importantly, we discovered that hepatic B cell lymphopoiesis did not cease after birth and that tolerance defects contributed to immunoglobulin G (IgG)-autoantibody accumulation in BA. In a rhesus-rotavirus induced BA model, depleting B cells or blocking antigen presentation ameliorated liver damage. In a pilot clinical study, we demonstrated that rituximab was effective in depleting hepatic B cells and restoring the functions of macrophages, Kupffer cells, and T cells to levels comparable to those of control subjects. In summary, our comprehensive immune profiling in infants with BA had educed that B-cell-modifying

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. MEDIUM
Pharmacol Ther · 2022 · PMID:34492237 · Q:0.33
ABSTRACT

Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that

CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis. MEDIUM
Int J Mol Sci · 2024 · PMID:38731899 · Q:0.00
ABSTRACT

The chemotactic cytokine fractalkine (FKN, chemokine CX3CL1) has unique properties resulting from the combination of chemoattractants and adhesion molecules. The soluble form (sFKN) has chemotactic properties and strongly attracts T cells and monocytes. The membrane-bound form (mFKN) facilitates diapedesis and is responsible for cell-to-cell adhesion, especially by promoting the strong adhesion of leukocytes (monocytes) to activated endothelial cells with the subsequent formation of an extracellular matrix and angiogenesis. FKN signaling occurs via CX3CR1, which is the only known member of the CX3C chemokine receptor subfamily. Signaling within the FKN-CX3CR1 axis plays an important role in many processes related to inflammation and the immune response, which often occur simultaneously and overlap. FKN is strongly upregulated by hypoxia and/or inflammation-induced inflammatory cytokine release, and it may act locally as a key angiogenic factor in the highly hypoxic tumor microenvironme

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia. MEDIUM
Biochem Biophys Res Commun · 2026 · PMID:41924777 · Q:0.00
ABSTRACT

CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which may include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre +/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region-and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral

Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone. MEDIUM
Immunity · 2026 · PMID:41923645 · Q:0.00
ABSTRACT

Glioblastoma (GB) cells infiltrate the brain parenchyma and colonize distant regions, driving recurrence and therapy resistance. Here, we examined dynamic microglial responses to infiltrating tumor cells during GB progression. Three-photon imaging in an autochthonous, immunocompetent GB mouse model enabled visualization of microglia-GB interactions at the far infiltration zone (FIZ) in the corpus callosum (CC). GB infiltration speed varied by anatomical location and tumor microtube (TM) number. Microglia increased surveillance in sparsely infiltrated areas but reduced it with higher GB density, revealing a biphasic response. Directional migration toward GB cells was restricted to microglial subsets within a defined spatial range, indicating heterogeneous reactivity. CX3CR1 deficiency enhanced microglial reactivity while limiting GB cell migration. Microglia depletion with the CSF1R inhibitor PLX5622 reduced GB cell migration and constrained TM plasticity. Thus, microglia respond to GB

Identification of suicide brain transcriptomic signatures using meta-analysis of multiple cohorts. MEDIUM
Transl Psychiatry · 2026 · PMID:41916959 · Q:0.00
ABSTRACT

Suicide remains a critical global public health issue, accounting for nearly one million deaths annually and imposing profound societal and economic burdens. Despite its urgency, the lack of diagnostic and predictive biomarkers continues to hinder the development of effective prevention and treatment strategies. This study presents a comprehensive meta-analysis that integrates publicly available postmortem brain transcriptomic datasets and a domestic cohort, encompassing 16 cohorts. The transcriptomic data, sourced from the Gene Expression Omnibus repository, were generated using various techniques, including traditional RNA sequencing, microarray methods, and single-cell RNA sequencing. Differential expression analyses were performed across multiple brain regions, with meta-analyses stratified by cortical regions, the dorsolateral prefrontal cortex (DLPFC), and combined. We further analyzed whether covariates may affect the identified genes. Three meta-analytic approaches were employe

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's diseas… MEDIUM
G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.
Adv Protein Chem Struct Biol · 2026 · PMID:41904008 · Q:0.00
ABSTRACT

Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C

Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcr… MEDIUM
Conserved ductular reaction mechanisms in biliary atresia and PSC derived from single-cell and spatial transcriptomics.
Cell Mol Gastroenterol Hepatol · 2026 · PMID:41903685 · Q:0.00
ABSTRACT

Primary sclerosing cholangitis (PSC) and biliary atresia (BA) both demonstrate the ductular reaction (DR), including biliary ductules, immune infiltration, and fibroblast activation. Advances in single-cell RNA sequencing and spatial transcriptomics have revolutionised our understanding of the DR fibro-inflammatory niche of these disorders. Recent studies using these techniques have also demonstrated that there are conserved mechanisms of fibro-inflammation across diseases and organ systems. Notably, epithelial, mesenchymal, and innate immune processes in the DR are shared between BA and PSC, including: pro-fibrogenic hepatocyte-to-cholangiocyte transdifferentiation, increased cholangiocyte senescence, accumulation of scar-/lipid-associated macrophages, Kupffer cell dysfunction, and activation of portal fibroblasts. In contrast, adaptive immune processes differ between the two disorders, including: transdifferentiation of Th17 into Th1 cells in BA, dominance of the Th17 axis in PSC, re

Identifies immunological mechanisms of neuroprotection in Parkinson's disease, suggesting relevance of microgl… MODERATE
Identifies immunological mechanisms of neuroprotection in Parkinson's disease, suggesting relevance of microglial modulation.
Front Aging Neurosci · 2026 · PMID:41788408 · Q:0.00
ABSTRACT

1. Front Aging Neurosci. 2026 Feb 18;18:1764634. doi: 10.3389/fnagi.2026.1764634. eCollection 2026. Systems-level molecular and immunological evidence identifies Th17/Treg modulation as a key...

Directly discusses chemokine networks and blood-brain barrier regulation, closely aligned with fractalkine axi… STRONG
Directly discusses chemokine networks and blood-brain barrier regulation, closely aligned with fractalkine axis hypothesis.
Biomolecules · 2026 · PMID:41897331 · Q:0.00
ABSTRACT

1. Biomolecules. 2026 Mar 5;16(3):395. doi: 10.3390/biom16030395. Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, Clinical Translation, and Precision Therapeutic...

Directly examines CX3CL1/CX3CR1 axis dysregulation in neurological disorder, strongly supporting hypothesis. STRONG
Acta Neuropathol Commun · 2026 · PMID:41863015
ABSTRACT

1. Acta Neuropathol Commun. 2026 Mar 20. doi: 10.1186/s40478-026-02274-2. Online ahead of print. CX3CL1/CX3CR1 axis dysregulation contributes to epileptogenic mechanisms in focal cortical...

[Corrigendum] Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism.
Int J Mol Med · 2026 · PMID:41930567 · Q:0.00
CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.
Sci Rep · 2026 · PMID:41932952 · Q:0.00
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation.
J Exp Med · 2026 · PMID:41758203 · Q:0.00
Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes.
NPJ Aging · 2026 · PMID:41946716 · Q:0.00
CD8(+) T(EMRA) cells: A double-edged sword in immunity and disease-Mechanisms and therapeutic targets.
Int Immunopharmacol · 2026 · PMID:41946125 · Q:0.00
Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects d…
Expression of MS4A4A on synovial infiltrating macrophages is a hallmark of rheumatoid arthritis and reflects disease severity.
Immunol Med · 2026 · PMID:41955527 · Q:0.00
Role of Cannabinoid Receptor Type 2 in Acute Behavioral Responses to Graft Versus Host Disease in Male Mice.
Cannabis Cannabinoid Res · 2026 · PMID:41958320 · Q:0.00

Opposing Evidence 8

Error fetching MEDIUM
J Inflamm Res · 2022 · PMID:35642214 · Q:0.33
ABSTRACT

Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.

Microglia in neurodegeneration. MEDIUM
Nat Neurosci · 2018 · PMID:30258234 · Q:0.33
ABSTRACT

The neuroimmune system is involved in development, normal functioning, aging, and injury of the central nervous system. Microglia, first described a century ago, are the main neuroimmune cells and have three essential functions: a sentinel function involved in constant sensing of changes in their environment, a housekeeping function that promotes neuronal well-being and normal operation, and a defense function necessary for responding to such changes and providing neuroprotection. Microglia use a defined armamentarium of genes to perform these tasks. In response to specific stimuli, or with neuroinflammation, microglia also have the capacity to damage and kill neurons. Injury to neurons in Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis, frontotemporal dementia, and chronic traumatic encephalopathy, results from disruption of the sentinel or housekeeping functions and dysregulation of the defense function and neuroinflammation. Pa

Constitutive expression of CX3CR1-BAC-Cre introduces minimal off-target effects in microglia MEDIUM
bioRxiv · 2024 · PMID:39554070 · Q:0.00
ABSTRACT

CX3CR1-Cre mouse lines have produced important advancements in our understanding of microglial biology. Recent studies have demonstrated the adverse effects of tamoxifen-induced CX3CR1-Cre expression during development, which include changes in microglial density, phenotype, and DNA damage, as well as anxiety-like behavior. However, the unintended effects of constitutive CX3CR1-BAC-Cre expression remain unexplored. Here, we characterized the effects of CX3CR1-BAC-Cre expression on microglia in CX3CR1-BAC-Cre+/- and CX3CR1-BAC-Cre-/- male and female littermates during early postnatal development and adulthood in multiple brain regions. Additionally, we performed anxiety-like behavior tests to assess changes caused by Cre expression. We found that CX3CR1-BAC-Cre expression causes subtle region- and sex-specific changes in microglial density, volume, and morphology during development, but these changes normalized by adulthood in all brain regions except the hippocampus. No behavioral effe

How neuroinflammation contributes to neurodegeneration. MEDIUM
Science · 2016 · PMID:27540165 · Q:0.33
ABSTRACT

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal lobar dementia are among the most pressing problems of developed societies with aging populations. Neurons carry out essential functions such as signal transmission and network integration in the central nervous system and are the main targets of neurodegenerative disease. In this Review, I address how the neuron's environment also contributes to neurodegeneration. Maintaining an optimal milieu for neuronal function rests with supportive cells termed glia and the blood-brain barrier. Accumulating evidence suggests that neurodegeneration occurs in part because the environment is affected during disease in a cascade of processes collectively termed neuroinflammation. These observations indicate that therapies targeting glial cells might provide benefit for those afflicted by neurodegenerative disorders.

CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. MEDIUM
Pharmacol Ther · 2022 · PMID:34492237 · Q:0.33
ABSTRACT

Neuroinflammation was initially thought of as a consequence of neurodegenerative disease pathology, but more recently it is becoming clear that it plays a significant role in the development and progression of disease. Thus, neuroinflammation is seen as a realistic and valuable therapeutic target for neurodegeneration. Neuroinflammation can be modulated by neuron-glial signaling through various soluble factors, and one such critical modulator is Fractalkine or C-X3-C Motif Chemokine Ligand 1 (CX3CL1). CX3CL1 is produced in neurons and is a unique chemokine that is initially translated as a transmembrane protein but can be proteolytically processed to generate a soluble chemokine. CX3CL1 has been shown to signal through its sole receptor CX3CR1, which is located on microglial cells within the central nervous system (CNS). Although both the membrane bound and soluble forms of CX3CL1 appear to interact with CX3CR1, they do seem to have different signaling capabilities. It is believed that

G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's diseas… MEDIUM
G-protein coupled receptor chemokine CX3CR1 influences extracellular Tau internalization in Alzheimer's disease.
Adv Protein Chem Struct Biol · 2026 · PMID:41904008 · Q:0.00
ABSTRACT

Alzheimer's Disease is characterized by significant alterations in the cytoskeleton, driven by hyperphosphorylation of the microtubule-associated protein Tau. This modification impairs Tau's ability to stabilize microtubules, leading to structural instability, disrupted axonal transport, and neuronal degeneration. Hyperphosphorylated Tau aggregates into neurofibrillary tangles and oligomers, exacerbating cellular dysfunction. The cytoskeleton, composed of actin filaments, microtubules, and intermediate filaments, is vital for maintaining cellular structure, intracellular transport, and signalling. G-protein coupled receptors, widely expressed in neuroglial cells, play critical roles in neuroinflammation, synaptic pruning, and cytoskeletal dynamics in neurodegenerative diseases. Extracellular Tau species interact with GPCRs, particularly in microglia and astrocytes, triggering neuroinflammatory responses and cytoskeletal remodelling. Key kinases such as Glycogen Synthase Kinase-3β and C

Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets. MEDIUM
Int J Mol Sci · 2025 · PMID:41465422 · Q:0.00
ABSTRACT

Astrocytes and microglia constitute nearly half of all central nervous system cells and are indispensable for its proper function. Both exhibit striking morphological and functional heterogeneity, adopting either neuroprotective (A2, M2) or proinflammatory (A1, M1) phenotypes in response to cytokines, pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns (DAMPs), toll-like receptor 4 (TLR4) activation, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling. Crucially, many of these phenotypic transitions arise during the earliest stages of neurodegeneration, when glial dysfunction precedes overt neuronal loss and may act as a primary driver of disease onset. This review critically examines glial-centered hypotheses of neurodegeneration, with emphasis on their roles in early disease phases: (i) microglial polarization from an M2 neuroprotective state to an M1 proinflammatory state; (ii) NLRP3 inflammasome assembly via P2X puri

CX3CR1: a potential microglia-specific PET imaging target in Alzheimer's and Parkinson's diseases. MEDIUM
Front Pharmacol · 2025 · PMID:41424797 · Q:0.00
ABSTRACT

Microglia are the resident immune cells of the central nervous system (CNS), playing a crucial role in maintaining brain homeostasis and mediating neuroimmune responses. The chemokine receptor CX3CR1, predominantly expressed on microglia, regulates microglial function via interactions with its neuronal ligand CX3CL1. The CX3CR1-CX3CL1 signaling exhibits complex, context-dependent roles in neurodegenerative diseases. In Alzheimer's disease (AD) and Parkinson's disease (PD) animal models, CX3CR1 deficiency shows paradoxical outcomes, attenuating or exacerbating amyloid-β (Aβ) and tau pathologies in AD, while consistently worsening α-synuclein-induced neurodegeneration in PD. Although CX3CR1 emerges as a promising therapeutic and diagnostic target, its complex role in microglial dynamics remains incompletely understood. Positron emission tomography (PET) imaging provides a powerful, noninvasive method for investigating biological processes in vivo. There is an urgent need to develop and v

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Description: Engineer synthetic C1q mimetics that bind to synaptic "eat-me" signals without activating downstream complement cascade, effectively saturating microglial recognition sites and preventing pathological synaptic elimination. These decoys would competitively inhibit authentic C1q binding while lacking the Fc-like domain necessary for microglial phagocytosis activation.

Target: C1Q complement component subunit A (C1QA) and microglial compleme

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Specific Weaknesses:

  • Selectivity Problem: C1q has essential physiological roles beyond synaptic pruning, including pathogen clearance and apoptotic cell removal. Broad C1q inhibition could compromise immune function and debris clearance.
  • Dosing Paradox: The therapeutic window may be extremely narrow - insufficient decoy concentration won't compete effectively, while excess may trigger non-specific immune responses.
  • Structural Complexity: C1q is a massiv

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Practical Feasibility Assessment: Synaptic Pruning Therapeutics

Hypothesis 1: Complement C1q Mimetic Decoy Therapy

Revised Confidence: 0.45

Druggability Assessment

Target Class: Protein-protein interaction (PPI) - historically challenging but increasingly tractable Chemical Matter:
  • Large molecule approach: Engineered proteins/peptides mimicking C1q globular heads (22 kDa each)
  • Small molecule approach: PPI inhibitors targeting C1q-CR3 interface (challenging given large interaction surface ~1,500 Ų)
  • Best bet: Antibody-based decoys or engineered protein f

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.250.500.75 created: post_process (2026-04-02 01:34)evidence: market_dynamics_seed (2026-04-02 18:16)score_update: post_process (2026-04-02T02:55)score_update: post_process (2026-04-02T04:15)evidence: evidence_update (2026-04-02T05:35)debate: debate_engine (2026-04-02T06:56)evidence: evidence_update (2026-04-02T08:16)debate: debate_engine (2026-04-02T09:36)evidence: evidence_update (2026-04-02T10:57)evidence: evidence_update (2026-04-02T12:17)evidence: evidence_update (2026-04-02T13:37)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-102026-04-15 Market PriceScoreevidencedebate 145 events
7d Trend
Stable
7d Momentum
▲ 2.7%
Volatility
Low
0.0154
Events (7d)
73
⚡ Price Movement Log Recent 15 events
Event Price Change Source Time
📄 New Evidence $0.531 ▲ 1.7% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.522 ▲ 3.8% evidence_batch_update 2026-04-13 02:18
Recalibrated $0.503 ▼ 2.5% 2026-04-12 05:13
Recalibrated $0.515 ▲ 3.3% 2026-04-10 19:56
Recalibrated $0.499 ▼ 1.1% 2026-04-10 15:58
Recalibrated $0.505 ▲ 1.3% 2026-04-10 15:53
Recalibrated $0.498 ▼ 1.6% 2026-04-08 18:39
Recalibrated $0.506 ▼ 0.5% 2026-04-06 04:04
Recalibrated $0.508 ▼ 0.7% 2026-04-04 16:38
Recalibrated $0.512 ▲ 0.4% 2026-04-04 16:02
📄 New Evidence $0.509 ▲ 1.8% evidence_batch_update 2026-04-04 09:08
Recalibrated $0.501 ▼ 14.6% 2026-04-03 23:46
Recalibrated $0.586 ▲ 8.5% market_dynamics 2026-04-03 01:06
Recalibrated $0.540 ▲ 1.1% market_dynamics 2026-04-03 01:06
Recalibrated $0.534 ▲ 15.4% 2026-04-02 21:55

Clinical Trials (4) Relevance: 13%

2
Active
2
Completed
0
Total Enrolled
Phase II
Highest Phase
ANX005 (Anti-C1q) in Huntington's Disease Phase II
Recruiting · NCT03999515
AL003 (Anti-SIGLEC-3/CD33) in Alzheimer's Phase I
Completed · NCT04777396
Daratumumab (Anti-CD38) in Alzheimer's Phase II
Recruiting · NCT04592874
Emtricitabine (NRTI) for Neuroinflammation Phase I
Completed · NCT03943264

📚 Cited Papers (70)

Paper:35642214
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
How neuroinflammation contributes to neurodegeneration.
Science (2016) · PMID:27540165
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Microglia in neurodegeneration.
Nat Neurosci (2018) · PMID:30258234
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.
International journal of molecular sciences (2025) · PMID:41465422
5 figures
Figure 1
Figure 1
Hypothesis of microglial polarization from the M2 to M1 phenotype and NLRP3 inflammasome activation. Panel ( A ) In the APP/PS1 mouse model of Alzheimer’s disease, microglia initia...
pmc_api
Figure 2
Figure 2
Hypothesis of crosstalk among microglia, astrocytes, and neurons. Panel schematic on the ( right ). An M1 polarized microglial cell releases proinflammatory mediators that act on A...
pmc_api
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.
J Inflamm Res (2022) · PMID:35642214
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases.
Pharmacol Ther (2022) · PMID:34492237
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Paper:20980594
No extracted figures yet
Paper:21778362
No extracted figures yet
Paper:25157208
No extracted figures yet
Paper:27156590
No extracted figures yet
Paper:27540165
No extracted figures yet
Paper:28133889
No extracted figures yet

📓 Linked Notebooks (1)

📓 Synaptic pruning by microglia in early AD — Analysis Notebook
CI-generated notebook stub for analysis sda-2026-04-01-gap-v2-691b42f1. Synaptic pruning by microglia in early AD
→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Wiki Pages

CX3CR1 — CX3C Chemokine Receptor 1geneYoga Therapy for NeurodegenerationtherapeuticYAP/TEAD Pathway Modulators for NeurodegenerationtherapeuticWnt Signaling Modulators for Neurodegenerationtherapeuticvitamin-d-therapy-neurodegenerationtherapeuticVitamin B Complex Therapy for NeurodegenerationtherapeuticVIP/VPAC Receptor Modulators for NeurodegenerationtherapeuticUrolithin A for NeurodegenerationtherapeuticUrolithin A for Neurodegenerationtherapeutictudca-udca-neurodegenerationtherapeuticTRPM8 Agonists for NeurodegenerationtherapeuticTriple Incretin Agonists (GLP-1/GIP/Glucagon) for therapeuticTREM2 Agonist Therapy for NeurodegenerationtherapeuticTranscranial Magnetic Stimulation Therapy for NeurtherapeuticTLR7/8/9 Antagonists for Neurodegenerationtherapeutic

KG Entities (34)

ANXA1APOEC1QC1QACOGNITIVE DECLINECX3CR1DAP12Fractalkine receptor / microglia-neuron HK2Microglial activation / TREM2 signalingP2RY12P38PI3KSOD1SYNAPTIC PRUNINGSynaptic function / plasticityTREM2TREM2-DAP12 microglial signalingeat_me_signalsfractalkine_signaling

Dependency Graph (1 upstream, 4 downstream)

Depends On
Microglial Purinergic Reprogrammingbuilds_on (1.0)
Depended On By
TREM2-mediated microglial tau clearance enhancementbuilds_on (1.0)Purinergic P2Y12 Inverse Agonist Therapybuilds_on (1.0)TREM2 Conformational Stabilizers for Synaptic Discriminationbuilds_on (0.6)Optogenetic Microglial Deactivation via Engineered Inhibitory Opsinsrefines (0.5)

Linked Experiments (9)

TREM2 Function in Alzheimer's Disease — From Risk Variant to Therapeutic Targetvalidation | tests | 0.40DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibitor Responseclinical | tests | 0.40FTD Microglia Role: Protective vs Destructive Mechanism Studyvalidation | tests | 0.40TREM2 Agonist Therapy for Parkinson's Disease — Experimental Designvalidation | tests | 0.40Microglial TREM2 Agonist In Vivo Efficacyvalidation | tests | 0.40Microglial Contributions to Huntington's Disease Pathogenesisvalidation | tests | 0.40Microglial Aging and Immune Memory in Neurodegeneration — Training the Brain's Mvalidation | tests | 0.40s:** - GPR32 knockout in microglia should worsen neuroinflammation if this is thfalsification | tests | 0.40Proposed experiment from debate on Synaptic pruning by microglia in early ADfalsification | tests | 0.40

Related Hypotheses

Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins
Score: 0.384 | neurodegeneration
SASP-Mediated Complement Cascade Amplification
Score: 0.703 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.692 | neurodegeneration
H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector
Score: 0.675 | neurodegeneration
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.670 | neurodegeneration

Estimated Development

Estimated Cost
$3M
Timeline
2.3 years

🧪 Falsifiable Predictions (5)

5 total 0 confirmed 0 falsified
sufficient vs C1q-deficient AD mice 2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment 3. Examine whether decoys prevent beneficial C1q functions like amyloid phagocytosis
pending conf: 0.60
Expected outcome: Confirmatory evidence for hypothesis
Falsified by: Failure of: sufficient vs C1q-deficient AD mice 2. Measure systemic immune function (bacterial clearance, autoantibody formation) during chronic decoy treatment 3. Examine whether decoys prevent beneficial C1q fu
response curves for both anti-inflammatory markers and synaptic preservation 3. Compare effects in microglia-specific vs pan-cellular CX3CR1 modulation
pending conf: 0.60
Expected outcome: Confirmatory evidence for hypothesis
Falsified by: Failure of: response curves for both anti-inflammatory markers and synaptic preservation 3. Compare effects in microglia-specific vs pan-cellular CX3CR1 modulation
penetrant P2Y12 inverse agonists
pending conf: 0.60
Expected outcome: Confirmatory evidence for hypothesis
Falsified by: Failure of: penetrant P2Y12 inverse agonists
specific metabolic inhibition using cell-type-specific delivery systems 2. Measure microglial viability and essential functions during forced metabolic reprogramming 3. Compare effects in different brain regions with varying baseline metabolic demands
pending conf: 0.60
Expected outcome: Confirmatory evidence for hypothesis
Falsified by: Failure of: specific metabolic inhibition using cell-type-specific delivery systems 2. Measure microglial viability and essential functions during forced metabolic reprogramming 3. Compare effects in different br
term opsin expression in neuroinflammatory conditions 3. Compare localized vs distributed optogenetic control for preventing synaptic loss 4. Assess whether benefits persist when light stimulation is discontinued
pending conf: 0.60
Expected outcome: Confirmatory evidence for hypothesis
Falsified by: Failure of: term opsin expression in neuroinflammatory conditions 3. Compare localized vs distributed optogenetic control for preventing synaptic loss 4. Assess whether benefits persist when light stimulation i

Knowledge Subgraph (75 edges)

associated with (3)

CX3CR1 neurodegeneration
ANXA1 neurodegeneration
TREM2 neurodegeneration

co associated with (14)

ANXA1 CX3CR1
ANXA1 P2RY12
C1QA HK2
ANXA1 C1QA
C1QA CX3CR1
...and 9 more

co discussed (38)

HK2 TREM2
HK2 P2RY12
HK2 C1Q
HK2 C1QA
HK2 CX3CR1
...and 33 more

contributes to (1)

SYNAPTIC PRUNING COGNITIVE DECLINE

fuels (1)

glycolysis microglial_activation

implicated in (7)

h-f99ce4ca neurodegeneration
h-1fe4ba9b neurodegeneration
h-ba3a948a neurodegeneration
h-38292315 neurodegeneration
h-513a633f neurodegeneration
...and 2 more

maintains (1)

fractalkine_signaling microglial_surveillance

mediates (2)

CX3CR1 fractalkine_signaling
ANXA1 phosphatidylserine_masking

participates in (4)

CX3CR1 Fractalkine receptor / microglia-neuron communication
HK2 Microglial activation / TREM2 signaling
ANXA1 Synaptic function / plasticity
TREM2 TREM2-DAP12 microglial signaling

rate limits (1)

HK2 glycolysis

regulates (2)

P2RY12 microglial_process_motility
TREM2 microglial_phagocytosis

suppresses (1)

phosphatidylserine_masking eat_me_signals

Mechanism Pathway for CX3CR1

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    CX3CR1["CX3CR1"] -->|mediates| fractalkine_signaling["fractalkine_signaling"]
    CX3CR1_1["CX3CR1"] -->|associated with| neurodegeneration["neurodegeneration"]
    CX3CR1_2["CX3CR1"] -->|participates in| Fractalkine_receptor___mi["Fractalkine receptor / microglia-neuron communication"]
    HK2["HK2"] -->|co discussed| CX3CR1_3["CX3CR1"]
    TREM2["TREM2"] -->|co discussed| CX3CR1_4["CX3CR1"]
    P2RY12["P2RY12"] -->|co discussed| CX3CR1_5["CX3CR1"]
    C1Q["C1Q"] -->|co discussed| CX3CR1_6["CX3CR1"]
    C1QA["C1QA"] -->|co discussed| CX3CR1_7["CX3CR1"]
    ANXA1["ANXA1"] -->|co discussed| CX3CR1_8["CX3CR1"]
    APOE["APOE"] -->|co discussed| CX3CR1_9["CX3CR1"]
    CX3CR1_10["CX3CR1"] -->|co discussed| P2RY12_11["P2RY12"]
    CX3CR1_12["CX3CR1"] -->|co discussed| SOD1["SOD1"]
    CX3CR1_13["CX3CR1"] -->|co discussed| HK2_14["HK2"]
    CX3CR1_15["CX3CR1"] -->|co discussed| C1Q_16["C1Q"]
    CX3CR1_17["CX3CR1"] -->|co discussed| C1QA_18["C1QA"]
    style CX3CR1 fill:#ce93d8,stroke:#333,color:#000
    style fractalkine_signaling fill:#81c784,stroke:#333,color:#000
    style CX3CR1_1 fill:#ce93d8,stroke:#333,color:#000
    style neurodegeneration fill:#ef5350,stroke:#333,color:#000
    style CX3CR1_2 fill:#ce93d8,stroke:#333,color:#000
    style Fractalkine_receptor___mi fill:#81c784,stroke:#333,color:#000
    style HK2 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_3 fill:#ce93d8,stroke:#333,color:#000
    style TREM2 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_4 fill:#ce93d8,stroke:#333,color:#000
    style P2RY12 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_5 fill:#ce93d8,stroke:#333,color:#000
    style C1Q fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_6 fill:#ce93d8,stroke:#333,color:#000
    style C1QA fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_7 fill:#ce93d8,stroke:#333,color:#000
    style ANXA1 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_8 fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_9 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_10 fill:#ce93d8,stroke:#333,color:#000
    style P2RY12_11 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_12 fill:#ce93d8,stroke:#333,color:#000
    style SOD1 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_13 fill:#ce93d8,stroke:#333,color:#000
    style HK2_14 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_15 fill:#ce93d8,stroke:#333,color:#000
    style C1Q_16 fill:#ce93d8,stroke:#333,color:#000
    style CX3CR1_17 fill:#ce93d8,stroke:#333,color:#000
    style C1QA_18 fill:#ce93d8,stroke:#333,color:#000

3D Protein Structure

🧬 CX3CR1 — PDB 7XBX Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Synaptic pruning by microglia in early AD

neurodegeneration | 2026-04-01 | completed